Laurus Labs (BOM:540222) Beta: 0.7668 (As of Jun. 30, 2026)


BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,502.90
GF Value ₹697.80
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Laurus Labs Beta?

Laurus Labs BOM:540222 +3.61% 66 Beta is 0.7668 as of Jun. 30, 2026. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹697.80 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-30), Laurus Labs's Beta is 0.7668.


Laurus Labs  (BOM:540222) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Laurus Labs Beta Related Terms


Laurus Labs Beta Historical Data

* Premium members only.

The historical data trend for Laurus Labs's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laurus Labs Beta Chart

Laurus Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 2.03 1.13 1.20 0.89

Laurus Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.20 1.09 0.66 0.95 0.89

BOM:540222 vs ZTS, UTHR: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Beta distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Beta falls into.


BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laurus Labs Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.7668 mean?
Laurus Labs (BOM:540222) has a Beta of 0.7668 as of Jun. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Laurus Labs and its competitors.
Is Laurus Labs' Beta too high?
Laurus Labs' current Beta is 0.7668. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Beta compare to ZTS and UTHR?
Laurus Labs' Beta of 0.7668 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Laurus Labs and its competitors. Laurus Labs's current Beta is 0.7668. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹697.80, compared to a current price of ₹1,502.90 — trading 115.4% above its estimated fair value. The current Beta is 0.7668. Laurus Labs' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Beta is 0.7668 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,502.90 is trading 115.4% above its estimated GF Value™ of ₹697.80. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Beta: 0.7668
  • GF Value™: ₹697.80 vs. price of ₹1,502.90 (115.4% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,502.90
Price
₹697.80
GF Value